2024-03-18 02:21:07 ET
Summary
- Younger generations need digital healthcare solutions. Hims' birth and ascent is a lesson in psychology.
- I disclose my original position of just under 50,000 shares at a cost basis of $5.50.
- I value Hims using a DCF and EPS table so investors will have a clear picture of my valuation and can calculate their own from my table.
- Read to see all the common arguments against Hims and my response.
- There are numerous risk to consider. It's important investors read until the end.
Introduction
I have been looking forward to sharing my updated thoughts on Hims & Hers Health ( HIMS ). I took a week to digest the earnings call in order to make sure I put together a thoughtful piece. I have published eleven articles on Hims going back to November 2021 . To put this in perspective, I have only published 50 other stock articles in the six years that I have been a writer on Seeking Alpha.
To be a successful investor is to be a disciplined investor . For every one stock I invest in, there are hundreds I discard. I don’t invest in or write on stocks I haven’t psychotically analyzed from every angle nor do I write articles for the money. I write because it’s a passion. Seeking Alpha could pay me free.99 for this article and I’d still write it (Richard: don’t get any ideas). And speaking of money, I disclosed my original Hims purchase of about 50,000 shares at a cost basis of $5.50.
You can do the math.
Disclosure
In late 2023, I opened my own registered investment advisory firm, DocShah Financial. I won’t bore you with the details, but we’ve had incredible growth and officially crossed $1,000,000 in assets under management on March 4, 2024. Integrity is at the core of everything I do, and as such, please make sure you read my disclosure at the bottom....
Read the full article on Seeking Alpha
For further details see:
Hims & Hers Health: A Lesson In Psychology